biotechnology

biotechnology

Umbrex is pleased to welcome Andrew McKee with Headland Strategy Group. Andrew has 15 years’ experience in biotechnology, pharmaceuticals, diagnostics, and other healthcare sectors. In his health care work, he specializes in consulting projects for healthcare executives that combine disruptive growth strategy expertise (e.g., disease area strategy, pipeline marketing/commercial evaluations, novel disruptive technologies) with distinctive consulting offerings (e.g., strategic decision-making workshop design and facilitation; qualitative market research with thought leaders). These projects necessarily require Andrew and his team to be multi-disciplinary problem-solvers and top-notch communicators.

Since 2012, Andrew has supervised 60+ projects on growth strategy and commercial strategy for executives from Fierce 15 biotechs to Top 5 pharma and across a wide range of therapeutic areas.  His background includes having worked for McKinsey and Company, Google, and Genentech in roles of increasing responsibility, and having trained and performed as a professional saxophonist. He holds BSE and MD degrees from Duke University, and is the lead author of scientific publications and is co-inventor on several patents that have been licensed by industry.  He is married and active with his family of three children.  He has a dedicated hobby of writing novels.  He also enjoys playing music (guitar, piano, drums, saxophones), hiking, camping, and sports with his family.